Decibel Cannabis Company (DB) Fair Value & Analysis
Healthcare · CA · Market cap C$69.2M
Fair value as of: Jun 26, 2026
From 13 valuation models · updated 3 days ago
Price vs Fair Value (12 months)
12‑month range C$0.0700 – C$0.1450 · fair‑value band C$0.0800 – C$0.1600 · the C$0.1200 price screens below the C$0.1200 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Decibel Cannabis Company (DB) currently trades at C$0.1200, while our model-based Fair Value estimate is C$0.1200 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Decibel Cannabis Company generated revenue of C$121M at a net margin of -2.6%. Revenue grew 40.5% year over year. It earns a return on equity of -5.2%. Net debt stands at C$27.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Decibel Cannabis Company Inc., an integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada. It is also involved in the extraction, processing, and manufacturing of cannabis derivative products, including vapes, cannabis infused pre-rolls, pre-rolls, edibles, and other value added products. The company also engages in the business-to-business cannabis product sales in the provinces of Saskatchewan and Alberta; and e-commerce end-user customers in the province of Saskatchewan. It offers its products under the Qwest, Vox, Blendcraft, and General Admission brands. Decibel Cannabis Company Inc. is headquartered in Calgary, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Decibel Cannabis Company reported revenue of C$113M in FY2025 versus C$52.5M in FY2021, a compound +21.1%/yr. Reported net income was −C$2.9M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Decibel Cannabis Company (DB) undervalued?
What is the fair value of DB?
What is the quality score of DB?
What is the revenue of Decibel Cannabis Company (DB)?
What is the net profit margin of DB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.